The usefulness of immunohistochemical evaluation of dihydropyrimidine dehydrogenase for rectal cancer treated with preoperative radiotherapy

Hepato-Gastroenterology

Volumn 50, Issue 52, 2003, Pages 906-911

  Komuro, Yasuhiro ^a   Watanabe, Toshiaki ^a   Tsuno, Nelson ^a   Kitayama, Joji ^a   Inagaki, Naohito ^b   Nishida, Miwa ^b   Nagawa, Hirokazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

Dihydropyrimidine dehydrogenase; Immunohistochemistry; Preoperative radiotherapy; Rectal cancer; Sandwich enzyme linked immunosorbent assay

Indexed keywords

BIOTIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; STREPTAVIDIN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MULTIMODALITY CANCER THERAPY; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECTUM CANCER;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; BLOTTING, WESTERN; COMBINED MODALITY THERAPY; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; OXIDOREDUCTASES; RECTAL NEOPLASMS;

EID: 0038001472     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N, Milano G: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30A:1517-1522.
2. Katona C, Kralovanszky J, Rosta A, Pandi E, Fonyad G, Toth K, Jeney A: Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients. Oncology 1998; 55:468-474.
3. McLeod HL, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, Koruth M, Cassidy J: Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br J Cancer 1998; 77:461-465.
4. Lu Z, Zhang R, Carpenter JT, Diasio RB: Decreased dihydropyrimidine dehydrogenese activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998; 4:325-329.
5. Ridge SA, Sludden J, Wei X, Sapone A, Brown O, Hardy S, Canney P, Fernandez-Salguero P, Gonzalez FJ, Cassidy J, McLeod HL: Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer 1998; 77:497-500.
6. Jiang W, Lu Z, He Y, Diasio RB: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 1997; 3:395-399.
7. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F, Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenese activity. J Clin Oncol 1995; 13:1663-1670.
8. Nita ME, Tominaga O, Nagawa H, Tsuruo T, Muto T: Dihydropyrimidine dehydrogenase but not thymidylate synthese expression is associated with resistance to 5-fluorouracil in colorectal cancer. Hepatogastroenterology 1998; 45:2117-2122.
9. Kirihara Y, Yamamoto W, Toge T, Nishiyama M: Dihydropyrimidine dehydrogenese, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 1999; 14:551-556.
10. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M, Takechi T, Okabe H, Fukushima M: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 1999; 5:883-889.
11. T, Kitayama J, Takei Y, Umetani N, Matsuda K, Nita ME, Hatano K, Tsuruo T, Nagawa H: Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression. Ann Oncol 2000; 11:273-279.
12. Swedish Rectal Cancer Trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336:980-987.
13. Dahlberg M, Glimelius B, Pahlman L: Improved survival and reduction in local failure rates after preoperative radiotherapy: evidence for the generalizability of the results of Swedish Rectal Cancer Trial. Ann Surg 1999; 229:493497.
14. Mendenhall WM, Bland KI, Copeland EM 3rd, Summers GE, Pfaff WW, Souba WW, Million RR: Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer? Ann Surg 1992; 215:696-705.
15. Myerson RJ, Michalski JM, King ML, Birnbaum E, Fleshman J, Fry R, Kodner I, Lacey D, Lockett MA: Adjuvant radiation therapy for rectal carcinoma: predictors of outcome. Int J Radiat Oncol Biol Phys 1995; 32:41-50.
16. Rich TA, Skibber JM, Ajani JA, Buchholz DJ, Cleary KR, Dubrow RA, Levin B, Lynch PM, Meterissian SH, Roubein LD, et al: Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 1995; 32:1025-1029.
17. Chari RS, Tyler DS, Anscher MS, Russell L, Clary BM, Hathorn J, Seigler HF: Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum. Ann Surg 1995; 221:778-786.
18. Minsky BD, Cohen AM, Kemeny N, Enker WE, Kelsen DP, Reichman B, Saltz L, Sigurdson ER, Frankel J: Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol 1992; 10:79-84.
19. Marsh RD, Chu NM, Vauthey JN, Mendenhall WM, Lauwers GY, Bewsher C, Copeland EM: Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy. Cancer 1996; 78:217-225.
20. Yokota H, Fernandez-Salguero P, Furuya H, Lin K, McBride OW, Podschun B, Schnackerz KD, Gonzalez FJ: cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem 1994; 269:23192-23196.
21. de StGroth SF: Production of monoclonal antibodies: strategy and tactics. J Immunol Methods 1980; 35:1-21.
22. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamaha H, Hirakawa YS Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M, Murai M, Sasaki H, Ozono S, Makuuchi H, Shimada Y, Onishi Y, Aoyagi S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H, Nakashima Y, Manabe T: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 2000; 17:33-38.
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.
24. Salvesen HB, Akslen LA: Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer 1999; 84:538-543.
25. Uetake H, Ichikawa W, Takechi T, Fukushima M, Nihei Z, Sugihara K: Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin Cancer Res 1999; 5:2836-2839.